Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

The operating evidence is constructive: H1 2026 organic sales grew 4.7%, balanced between 2.5% volume and 2.2% price, adjusted EBIT margin increased 50 basis points, and the productivity programme delivered EUR 90 million of savings. The counterweight is incomplete separation execution: adjusted EBITDA margin was 18.7% versus 19.0% a year earlier, including material TSA and acquired-business effects.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026
Low · most bearish analyst$16.20
Mean target$18.65
High · most bullish analyst$20.20
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$16.2023%

Organic growth falls below guidance as volume momentum weakens or pricing becomes harder to sustain, while TSA exits and acquired-business integration take longer or cost more than planned. Under that outcome, savings would be absorbed by execution costs rather than producing the expected margin expansion.

Base CaseCentral scenario
$18.6558%
Matches the consensus mean

Organic sales growth remains within the 3%-5% FY 2026 range, productivity offsets part of the remaining separation and acquisition burden, and margins improve on a comparable basis while reported improvement remains modest.

Bull CaseUpside scenario
$20.2019%

Organic growth remains near or above the upper end of FY 2026 guidance, volume stays positive, productivity savings accumulate as planned, and TSA exits remove a material source of margin drag. This would strengthen evidence that the independent company can convert its global brand scale into sustained profitable growth.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • H1 2026 organic sales growth of 4.7% was balanced between 2.5% volume and 2.2% price, indicating growth was not dependent solely on price increases.
  • Adjusted EBIT increased to EUR 716 million, adjusted EBIT margin rose 50 basis points to 15.3%, and EUR 90 million of productivity savings was delivered in H1 2026.
Sign in / Sign up to read more
Key Investment Risks
  • H1 2026 adjusted EBITDA margin declined to 18.7% from 19.0%; TSA effects reduced margin by 70 basis points and the India acquisition reduced it by another 30 basis points.
  • The company has a short record as an independently operated and listed business, making TSA exits, systems replacement, acquisition integration and delivery of the remaining productivity programme central execution risks.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.